New combo aims to crush 'Bad' cholesterol particle that other drugs miss
NCT ID NCT06496243
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This 16-week study tests whether a daily pill (obicetrapib) plus a twice-monthly shot (evolocumab, sold as Repatha) can lower a fatty particle called lipoprotein(a) that raises heart disease risk. About 69 adults with mildly high cholesterol and elevated Lp(a) will take the pill alone for 8 weeks, then add the shot for another 8 weeks. The goal is to see if the combination works better than the pill alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
obicetrapib and evolocumab (Repatha)
What this could lead to
If successful, this could point toward a new combination treatment to lower Lp(a), a stubborn risk factor for heart disease.
What could go wrong
This is a small, early-phase study with only 69 people and no placebo group. Results may not hold up in larger trials, and the long-term benefits or risks are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UPenn
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact